描述一种新的Hsp110抑制剂作为一种潜在的抗真菌剂
Cancan Sun1, Yi Li2,3, Justin M Kidd1
1Department of Physiology and Biophysics, School of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
Journal of fungi (Basel, Switzerland)
|November 26, 2024
概括
一种新型化合物,2H,通过抑制真菌热冲击蛋白110 (Hsp110) 伴侣功能,表现出广泛的抗真菌活性. 口服可以提高治疗真菌感染的疗效.
科学领域:
- 菌类学 菌类学是指菌类学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 真菌感染对全球健康构成重大威胁,需要开发新型抗真菌剂.
- 热冲击蛋白110 (Hsp110s) 是真核生物中关键的分子陪伴者,是抗真菌药物开发的有希望的目标.
- 向真菌Hsp110s提供了一种潜在的策略来对抗耐药性真菌病原体.
研究的目的:
- 评估一种新型化合物2H对真菌病原体的抗真菌潜力.
- 为了研究2H的作用机制,特别是它对真菌Hsp110伴侣活性的影响.
- 评估2H的药理动力学特征,以确定临床应用的最佳输送途径.
主要方法:
- 在体外评估2H对来自*Candida auris*的Hsp110伴侣活性的影响.
- 对2H在抑制*Cryptococcus neoformans**生长中的有效性进行评估.
- 药理动力学分析比较2H的口服和静脉注射.
主要成果:
- 2H表现出广泛的抗真菌活性.
- 该化合物有效地破坏了*Candida auris* Hsp110.0的体外伴侣活动.
- 2H抑制了新型菌 (Cryptococcus neoformans) 的生长.
- 药物动力学研究表明,与静脉注射相比,口服药物的有效性可能会提高,这突显了AUC/MIC比率的重要性.
结论:
- 化合物2H是向真菌Hsp110s以对抗真菌感染的有希望的候选物.
- 2H在体外对关键的真菌病原体具有显著的抗真菌活性.
- 优化药物动力学特征,特别是AUC/MIC比率,对于2H作为抗真菌疗法的临床进展至关重要.
相关概念视频
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
01:30Inhibitors of Viral Protein Synthesis
58
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
58
01:15Antifungal Agents
119
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
119